Drug Search Results
More Filters [+]

ABT-436

Alternative Names: abt-436, abt436, abt 436
Latest Update: 2022-10-03
Latest Update Note: PubMed Publication

Product Description

for Alcohol Dependence (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01613014)

Mechanisms of Action: V3 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ABT-436

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Depressive Disorder, Major|Alcoholism|Binge Drinking

Phase 1: Depressive Disorder, Major|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCIG-004

P2

Completed

Binge Drinking|Alcoholism

2015-05-01

M11-733

P2

Terminated

Depressive Disorder, Major

2013-10-01

M12-674

P1

Completed

Depressive Disorder, Major

2011-09-01

M11-731

P1

Completed

Healthy Volunteers

2010-02-01

Recent News Events